Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Consensus Price Target of GBX 2,085.83

Key Points

• Hikma Pharmaceuticals has a consensus “Buy” rating from six analysts, with an average 12-month price target of GBX 2,085.83.
• Recent broker actions were positive: Berenberg raised its target to GBX 2,100, while Citigroup increased its target to GBX 1,870; Jefferies and Deutsche Bank maintained “Buy” ratings.
• Shares opened at GBX 1,676, down 1.1%, while insider Tobias Hestler purchased 7,500 shares for £123,600. Insiders collectively own 22.26% of the company.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) has earned a consensus recommendation of "Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is GBX 2,085.83.

Several analysts have recently commented on HIK shares. Berenberg Bank increased their price target on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research note on Friday, September 25th. Citigroup raised their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th.

Insider Buying and Selling

In other news, insider Tobias Hestler bought 7,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by company insiders.

Hikma Pharmaceuticals Trading Down 1.1%

LON HIK opened at GBX 1,676 on Friday. The firm has a 50-day moving average price of GBX 1,611.73 and a 200 day moving average price of GBX 1,529.02. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The stock has a market capitalization of £3.47 billion, a P/E ratio of 9.52, a P/E/G ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,865.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.